Literature DB >> 17493656

The design of artificial retroviral restriction factors.

Melvyn W Yap1, Gulnahar B Mortuza, Ian A Taylor, Jonathan P Stoye.   

Abstract

In addition to the ability to bind the retroviral capsid protein, the retroviral restriction factors Fv1, Trim5alpha and Trim5-CypA share the common property of containing sequences that promote self-association. Otherwise Fv1 and Trim5alpha appear unrelated. Mutational analyses showed that restriction was invariably lost when changes designed to disrupt the sequences responsible for multimerization were introduced. A novel restriction protein could be obtained by substituting sequences from the self-associating domain of Fv1 for the Trim5 sequences in Trim5-CypA. Similarly, a fusion protein containing cyclophilin A joined to arfaptin2, a protein known to form extended dimers, was also shown to restrict HIV-1. Hence, multimerization of a capsid-binding domain could be the common minimum design feature for capsid-dependent retroviral restriction factors. However, not all domains that promote multimerization can substitute for the N-terminal domains of Fv1 and Trim5alpha. Moreover, only CypA can provide a capsid-binding site with different N-terminal domains. It is suggested that the spatial relationship between the multiple target binding sites may be important for restriction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17493656     DOI: 10.1016/j.virol.2007.04.005

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  44 in total

1.  Hexagonal assembly of a restricting TRIM5alpha protein.

Authors:  Barbie K Ganser-Pornillos; Viswanathan Chandrasekaran; Owen Pornillos; Joseph G Sodroski; Wesley I Sundquist; Mark Yeager
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

2.  Chance favors a prepared genome.

Authors:  Jonathan P Stoye; Melvyn W Yap
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-25       Impact factor: 11.205

3.  The TRIM5alpha B-box 2 domain promotes cooperative binding to the retroviral capsid by mediating higher-order self-association.

Authors:  Xing Li; Joseph Sodroski
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

Review 4.  Novel approaches to inhibiting HIV-1 replication.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Antiviral Res       Date:  2009-09-24       Impact factor: 5.970

5.  Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp.

Authors:  Felipe Diaz-Griffero; Alak Kar; Mark Lee; Matthew Stremlau; Eric Poeschla; Joseph Sodroski
Journal:  Virology       Date:  2007-10-24       Impact factor: 3.616

6.  General Model for Retroviral Capsid Pattern Recognition by TRIM5 Proteins.

Authors:  Jonathan M Wagner; Devin E Christensen; Akash Bhattacharya; Daria M Dawidziak; Marcin D Roganowicz; Yueping Wan; Ruth A Pumroy; Borries Demeler; Dmitri N Ivanov; Barbie K Ganser-Pornillos; Wesley I Sundquist; Owen Pornillos
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

7.  Determinants of the higher order association of the restriction factor TRIM5alpha and other tripartite motif (TRIM) proteins.

Authors:  Xing Li; Darwin F Yeung; Ann M Fiegen; Joseph Sodroski
Journal:  J Biol Chem       Date:  2011-06-16       Impact factor: 5.157

8.  The specificity of TRIM5 alpha-mediated restriction is influenced by its coiled-coil domain.

Authors:  Pierre V Maillard; Gabriela Ecco; Millán Ortiz; Didier Trono
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

9.  Independent evolution of an antiviral TRIMCyp in rhesus macaques.

Authors:  Sam J Wilson; Benjamin L J Webb; Laura M J Ylinen; Ernst Verschoor; Jonathan L Heeney; Greg J Towers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

10.  Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species.

Authors:  Cesar A Virgen; Zerina Kratovac; Paul D Bieniasz; Theodora Hatziioannou
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.